Single-walled carbon nanotube-loaded doxorubicin and Gd-DTPA for targeted drug delivery and magnetic resonance imaging. (7th February 2017)

• Record Type: Journal Article
• Authors: Yan, Chenyu; Chen, Chengqun; Hou, Lin; Zhang, Huijuan; Che, Yingyu; Qi, Yuedong; Zhang, Xiaojian; Cheng, Jingliang; Zhang, Zhenzhong
• Is Part Of: Journal of drug targeting. Volume 25:Number 2(2017)
• Page Start: 163
• Page End: 171
• Publication Date: 2017-02-07
• Subjects: Targeted drug delivery -- tumor diagnosis -- magnetic resonance imaging -- SWCNTs -- NGR; Drug delivery systems -- Periodicals; Drug Delivery Systems; Vehicles; Drug Administration Routes; Drug Evaluation; 615.7
• DOI: 10.1080/1061186X.2016.1221958
• Languages: English
• ISSNs: 1061-186X

Abstract

Abstract: An aspargine-glycine-arginine (NGR) peptide modified single-walled carbon nanotubes (SWCNTs) system, developed by a simple non-covalent approach, could be loaded with the anticancer drug doxorubicin (DOX) and magnetic resonance imaging (MRI) contrast agent gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA). This DOX- and Gd-DTPA-loaded NGR functionalized SWCNTs (DOX/NGR-SWCNTs/Gd-DPTA) retained both cytotoxicity of DOX and MRI contrast effect of Gd-DPTA. This drug delivery system showed excellent stability in physiological solutions. This DOX/NGR-SWCNTs/Gd-DPTA system could accumulate in tumors and enter into tumor cells, which facilitated combination chemotherapy with diagnosis of tumor in one system. An excellent in vitro anti-tumor effect was shown in MCF-7 cells treated by DOX/NGR-SWCNTs/Gd-DPTA, compared with DOX solution, DOX/SWCNTs and DOX/SWCNTs/Gd-DPTA. In vivo data of DOX/NGR-SWCNTs/Gd-DPTA group in tumor-bearing mice further confirmed that this system performed much higher tumor targeting capacity and anti-tumor efficacy than other control groups.